Completion of submission batches and NDA-ready CMC package strengthens regulatory foundation for upcoming Phase 2b/3 trials and underscores Sen-Jam’s leadership in immunoregulation and inflammaging. HUNTINGTON, N.Y., Sept. 26, 2025 /PRNewswire/ — Sen-Jam Pharmaceutical, in partnership […]
Groundbreaking anti-inflammatory approach targets root cause of alcohol-induced morning-after symptoms, supporting greater vitality and productivity worldwide. HUNTINGTON, N.Y., Nov. 19, 2024 /PRNewswire/ — Sen-Jam Pharmaceutical announced recently the initiation of a Phase 2 clinical trial for […]
